Inhibition of sphingosine-1-phosphate phosphatase 1 promotes cancer cells migration in gastric cancer: Clinical implications

We have recently noticed an accidental error in part of a figure which appeared in the above‑mentioned article. In Fig. 3A, the image for the HGC27‑pEF, 15 h panel was mistakenly replicated as the HGC27‑KD, 0 h panel in the same figure, and the AGS‑pEF, 15 h and AGS KD, 0 h panels were mistakenly switched with each other. We have reviewed the original files and the individual figures for the submitted composite figure, and realized that the error occurred when we produced the composite figure by marrying the individual images to the final figure. The same image was accidentally pasted twice without us being fully aware of the error. We have identified all the original images, and the corrected version of Fig. 3 is shown below. We regret that this error occurred, and thank the Editor for affording us the opportunity to publish this Corrigendum. [the original article was published in the Oncology Reports 34: 1977-1987, 2015; DOI: 10.3892/or.2015.4162].

[1]  Danny Vesprini,et al.  miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. , 2013, Cancer research.

[2]  J. Ji,et al.  Expression of signal-induced proliferation-associated gene 1 (SIPA1), a RapGTPase-activating protein, is increased in colorectal cancer and has diverse effects on functions of colorectal cancer cells. , 2012, Cancer genomics & proteomics.

[3]  M. Shah,et al.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Joon-Oh Park,et al.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Y. Ohashi,et al.  Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Milstien,et al.  Sphingosine-1-phosphate phosphohydrolase-1 regulates ER stress-induced autophagy , 2011, Cell Death and Differentiation.

[7]  D. C. Simpson,et al.  Sphingosine‐1‐phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  P. Xia,et al.  Sphingosine 1-phosphate, a key mediator of the cytokine network: juxtacrine signaling. , 2011, Cytokine & growth factor reviews.

[9]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[10]  Cheng Luo,et al.  SPHINGOSINE-1-PHOSPHATE: A MISSING COFACTOR FOR THE E3 UBIQUITIN LIGASE TRAF2 , 2010, Nature.

[11]  T. Huxford,et al.  The crystal structure of sphingosine-1-phosphate in complex with a Fab fragment reveals metal bridging of an antibody and its antigen , 2009, Proceedings of the National Academy of Sciences.

[12]  S. Milstien,et al.  Regulation of Histone Acetylation in the Nucleus by Sphingosine-1-Phosphate , 2009, Science.

[13]  Jacques Ferlay,et al.  Recent patterns in gastric cancer: A global overview , 2009, International journal of cancer.

[14]  W. Jiang,et al.  Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. , 2009, European journal of cancer.

[15]  S. Spiegel,et al.  Role of Sphingosine-1-Phosphate Phosphohydrolase 1 in the Regulation of Resistance Artery Tone , 2008, Circulation research.

[16]  A. Cervantes,et al.  The treatment of advanced gastric cancer: current strategies and future perspectives. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  H. Bonkovsky,et al.  Vascular Endothelium As a Contributor of Plasma Sphingosine 1-Phosphate , 2008, Circulation research.

[18]  Yusuf A. Hannun,et al.  Principles of bioactive lipid signalling: lessons from sphingolipids , 2008, Nature Reviews Molecular Cell Biology.

[19]  David Cunningham,et al.  East meets west in the treatment of gastric cancer. , 2007, The New England journal of medicine.

[20]  F. Rivera,et al.  Chemotherapy of advanced gastric cancer. , 2007, Cancer treatment reviews.

[21]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[22]  N. Petrelli The debate is over; it's time to move on. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Chun,et al.  Lysophospholipid G Protein-coupled Receptors* , 2004, Journal of Biological Chemistry.

[24]  Korey R. Johnson,et al.  Role of Human Sphingosine-1-phosphate Phosphatase 1 in the Regulation of Intra- and Extracellular Sphingosine-1-phosphate Levels and Cell Viability* , 2003, Journal of Biological Chemistry.

[25]  A. Falcone Future strategies and adjuvant treatment of gastric cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  A. Kihara,et al.  Identification and Characterization of a Novel Human Sphingosine-1-phosphate Phosphohydrolase, hSPP2* , 2003, The Journal of Biological Chemistry.

[27]  S. Payne,et al.  Sphingosine‐1‐phosphate: dual messenger functions , 2002, FEBS letters.

[28]  S. Milstien,et al.  Sphingosine-1-phosphate phosphohydrolase in regulation of sphingolipid metabolism and apoptosis , 2002, The Journal of cell biology.

[29]  T. Hla,et al.  Lysophospholipids--Receptor Revelations , 2001, Science.

[30]  Y. Hannun,et al.  Cystic Fibrosis Transmembrane Regulator Regulates Uptake of Sphingoid Base Phosphates and Lysophosphatidic Acid , 2001, The Journal of Biological Chemistry.

[31]  R. Mansel,et al.  A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  S. Mandala Sphingosine-1-phosphate phosphatases. , 2001, Prostaglandins & other lipid mediators.

[33]  S. Spiegel,et al.  Molecular cloning and characterization of a lipid phosphohydrolase that degrades sphingosine-1- phosphate and induces cell death. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[34]  K. Matsumoto,et al.  Antagonistic effect of NK4, a novel hepatocyte growth factor variant, on in vitro angiogenesis of human vascular endothelial cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  Y. Hannun Functions of Ceramide in Coordinating Cellular Responses to Stress , 1996, Science.

[36]  W. Jiang,et al.  Inhibition of hepatocyte growth factor-induced motility and in vitro invasion of human colon cancer cells by gamma-linolenic acid. , 1995, British Journal of Cancer.

[37]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.